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Abstract
Introduction: The preventive impact of hospital-acquired infection (HAI) surveillance is difficult to assess. Our
objective was to investigate the effect of HAI surveillance disruption on ventilator-associated pneumonia (VAP)
incidence.
Methods: A quasi-experimental study with an intervention group and a control group was conducted between
1 January 2004 and 31 December 2010 in two intensive care units (ICUs) of a university hospital that participated
in a national HAI surveillance network. Surveillance was interrupted during the year 2007 in unit A (intervention
group) and was continuous in unit B (control group). Period 1 (pre-test period) comprised patients hospitalized
during 2004 to 2006, and period 2 (post-test period) involved patients hospitalized during 2008 to 2010. Patients
hospitalized ≥48 hours and intubated during their stay were included. Multivariate Poisson regression was fitted to
ascertain the influence of surveillance disruption.
Results: A total of 2,771 patients, accounting for 19,848 intubation-days at risk, were studied; 307 had VAP. The
VAP attack rate increased in unit A from 7.8% during period 1 to 17.1% during period 2 (P <0.001); in unit B, it was
7.2% and 11.2% for the two periods respectively (P = 0.17). Adjusted VAP incidence rose in unit A after surveillance
disruption (incidence rate ratio = 2.17, 95% confidence interval 1.05 to 4.47, P = 0.036), independently of VAP trend;
no change was observed in unit B. All-cause mortality and length of stay increased (P = 0.028 and P = 0.038,
respectively) in unit A between periods 1 and 2. In unit B, no change in mortality was observed (P = 0.22), while
length of stay decreased between periods 1 and 2 (P = 0.002).
Conclusions: VAP incidence, length of stay and all-cause mortality rose after HAI surveillance disruption in ICU,
which suggests a specific effect of HAI surveillance on VAP prevention and reinforces the role of data feedback
and counselling as a mechanism to facilitate performance improvement.
Introduction
Ventilator-associated pneumonia (VAP) is a major con-
cern in intensive care units (ICUs) because of its high
incidence and related mortality [1]. In the French
national surveillance system of hospital-acquired infec-
tions (HAIs) in ICUs, 12.4% of intubated patients in 2010
developed VAP during hospital stay, the most frequent
HAI site in ICU populations [2]. Mortality attributable to
VAP has been reported to be as high as 40 to 50% [1],
with a recent cohort study estimating a two-month attri-
butable mortality of 5.9% [3]. It has been postulated that
at least 20% of HAIs could be prevented with the imple-
mentation of appropriate measures [4-6], as several
investigations with multifaceted interventions have noted
decreases up to 70% in VAP rates [7-9]. HAI surveillance
might have a protective effect against HAI occurrence.
However, the strength and causality of the association* Correspondence: thomas.benet@chu-lyon.fr1Infection Control and Epidemiology Unit, Edouard Herriot Hospital, Hospices
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between surveillance and HAI incidence reduction are
difficult to estimate.
Several studies have demonstrated decreased HAI inci-
dence shortly after the implementation of nation-wide
surveillance [10-15]. For example, the Krankenhaus
Infektions Surveillance System in Germany reported a
20% decline of nosocomial pneumonia incidence between
the first and third years [11,16]. However, HAI rates at
implementation of surveillance were high [10-12]. Also,
the diminution of incidence could be explained in part by
regression to the mean [17]. Evaluation did not include a
control group. The decrease of HAI in these studies
could be ascribed to confounding factors, such as disease
severity or modification of care practices. Moreover, it
has been underlined that investigations into VAP preven-
tion should present benefits in patient outcome (mortal-
ity and duration of stay) in addition to reduction of VAP
incidence [18].
We hypothesize a converse relationship compared to
that suggested previously, namely, disruption of HAI sur-
veillance might induce an increase in HAI rates. It is diffi-
cult to perform controlled randomized trials to confirm or
refute this premise because of logistic reasons and since
HAI rates in units without surveillance are unknown.
A quasi-experimental design permitted us to test the
above supposition [17,19,20]. A unit with continuous
surveillance served as a control group, while a unit with
surveillance disruption was the intervention group. There-
fore, the study objective was to assess the effect of HAI
surveillance disruption on VAP incidence in ICUs with a
quasi-experimental design.
Materials and methods
Study setting and intervention
A quasi-experimental study with intervention and control
groups was undertaken between 2004 and 2010 in two
ICUs of Edouard Herriot Hospital in Lyon, France (units
A and B, respectively). Unit A is a medical/surgical poly-
valent ICU which contains 12 single rooms. Unit B is a
medical polyvalent ICU with 15 single rooms. The two
units did not differ in their staff/bed ratio, but both con-
formed to French law. These ICUs have participated in a
national HAI surveillance network since 1999, according
to a programme described elsewhere [15,21,22]. Surveil-
lance is based on prospective collection of HAIs in units
over the years that permits incidence calculation. A nurse
or physician of the infection control unit of our hospital
is regularly present in each unit for surveillance and to
discuss prevention practices with ICU staff. Feedback is
provided annually to ICU physicians and nurses by the
infection control team, and a summary of the results is
sent each semester to heads of both units. During surveil-
lance periods, similar expertise and counselling were
imparted in each unit by the infection control staff.
Usually, surveillance is continuous and conducted each
year. In unit A, surveillance was interrupted because of
infection control team re-organisation in 2007 but was
continuous in 2004 to 2006 and 2008 to 2010. Also, the
combination of the frequent physical presence of infec-
tion control staff for surveillance and data feedback was
stopped in unit A in 2007. In unit B, surveillance was not
interrupted between 2004 and 2010. The intervention
was HAI surveillance disruption in unit A in 2007. In
other words, the intervention group was unit A with HAI
surveillance disruption in 2007, and the control group
was unit B with no HAI surveillance disruption in 2007.
The pre-test period (period 1) included patients dis-
charged between 1 January 2004 and 31 December 2006,
and the post-test period (period 2) comprised patients
discharged between 1 January 2008 and 31 December
2010.
No other specific intervention in VAP prevention was
implemented selectively in unit A or unit B between
periods 1 and 2. Both units followed the same
recommendations.
Study population
All patients hospitalised ≥48 hours in the ICUs were
entered in the surveillance programme until their dis-
charge. Data were collected prospectively over the years
by infection control nurses or physicians on a standar-
dised form and incorporated demographic characteristics,
underlying disease severity, risk factors for HAIs, expo-
sure to mechanical ventilation, date and site of infection,
etiological agents and patient outcome. All patients, hos-
pitalized in ICUs ≥48 hours and intubated or tracheoto-
mised during ICU stay, were analysed.
Definitions of VAP
VAP [23] was defined according to the following criteria
[24]:
- Chest X-rays exhibiting lung infiltrates;
- Temperature >38°C or leukocyte count >12,000/
mm3 or <4,000/mm3;
- One of the following: 1) sputum modification, 2)
suggestive auscultation, 3) low oxyhaemoglobin
saturation, or 4) increased pulmonary oxygen
consumption;
- And one of the following: 1) directed broncho-
alveolar lavage (BAL)-positive culture at a threshold
of 104 cfu/ml in BAL or 103 cfu/ml in mini-BAL [25],
2) fibreoptic bronchoscopy specimen-positive culture
at a threshold of 106 cfu/ml, or 3) one of the follow-
ing: positive pleural or blood cultures without any
other site of infection, pulmonary or pleural abscess,
histopathological evidence of pneumonia or cultures
positive for specific agents. In patients presenting
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consecutive VAP episodes, only the first episode was
considered.
Statistical analysis
Firstly, descriptive analysis was performed. Quantitative
variables were reported as number and percentage, and
qualitative variables, as mean ± standard deviation (SD).
The VAP “attack rate” was the number of VAPs per 100
intubated patients, and VAP incidence was the number
of VAPs per 1,000 intubation-days at risk.
Secondly, analysis was conducted with Poisson regres-
sion to assess temporal trends and the effect of surveil-
lance disruption [26]. Bivariate Poisson regression was
fitted with number of VAPs as dependent variable, time
(per quarter) and HAI surveillance disruption in 2007 as
independent variables and the number of intubation-
days at risk as offset. The following potential confound-
ing factors were tested, first by univariate analysis:
gender, age, simplified acute physiological score II (SAP-
SII) at admission, reason for admission (medical, sur-
gery), immunosuppression, and antibiotics received at
admission. Backward step-wise multivariate analysis fol-
lowed. Trends (per quarter) and HAI surveillance dis-
ruption in 2007 were forced into the model; potential
confounding factors were entered initially if their
P-value after univariate analysis was ≤0.15; models were
compared by the log-likelihood-ratio test. A full model
was fitted with two independent and all potential con-
founding factors. All statistical tests were two-tailed, and
P <0.05 was considered as statistically significant. Miss-
ing data were avoided by complete case analysis.
Studies, such as this one, do not require ethics com-
mittee approval because they are based on an observa-
tional surveillance database approved under national
regulations (Comité National Informatique et Liberté).
According to French law, current surveillance of noso-
comial infections in hospital and epidemiological obser-
vational surveys do not need institutional review board
authorization or written consent.
Results
Study participants
Of the 4,411 patients included in the surveillance of
both units during the study period, 2,915 (61.1%) were
exposed to mechanical ventilation during their hospital
stay. Data were missing for 4.9% (n = 144) of intubated
patients and were, therefore, excluded.
Totally, 2,771 patients, accounting for 37,330 hospita-
lisation days, 26,768 intubation-days and 19,848 intuba-
tion-days at risk, were analysed. Among them, 940
(34%) were hospitalised in unit A, and 1,831 (66%) in
unit B. Overall, 62% (n = 1,724) were men, and mean ±
SD age was 60 ± 16 years. Totally, 61% (n = 1,694)
received antibiotics at admission, 41% (n = 1,142) came
from home, and 26% (n = 721) were immunosup-
pressed. Mean ± SD SAPSII score was 53 ± 20. All-
cause in-hospital mortality was 26% (n = 712).
Overall, 307 patients had VAP. The VAP attack rate
was 11.1 per 100 intubated patients and the VAP inci-
dence rate was 15.5 (95% confidence interval (95% CI)
13.8 to 17.3) per 1,000 intubation-days at risk.
Characteristics by group and period
Table 1 reports the characteristics of hospitalised
patients by group and period. In the intervention group
with surveillance interrupted in 2007, patients hospita-
lised during period 2 compared to period 1 more often
came from home (P = 0.004), were more immunosup-
pressed (P <0.001), more often had surgery as diagnosis
category (P <0.001), received antibiotics less frequently
at admission (P <.001), were older (P = 0.022), and pre-
sented lower mean SAPSII (P <0.001). In the control
group with continuous surveillance, patients hospitalised
during period 2 compared to period 1 were less likely to
come from home (P <0.001), were more immunosup-
pressed (P <0.001), and received antibiotics more fre-
quently at admission (P <0.001).
Duration of exposure by group and period
In the intervention group with surveillance interrupted
in 2007, mean length of ICU stay and of invasive
mechanical ventilation was longer during period 2 com-
pared to period 1 (P = 0.038 and P = 0.007, respec-
tively). In the control group, the length of invasive
mechanical ventilation was shorter during period 2 com-
pared to period 1 (P = 0.0023).
In patients who had VAP, mean ± SD length of invasive
mechanical ventilation before VAP onset did not change
between periods 1 and 2 in the intervention group (11.6
± 12.5 days vs. 14.0 ± 15.0 days, respectively, P = 0.4) and
in the control group (13.1 ± 11.6 days vs. 10.4 ± 9.9 days,
respectively, P = 0.11). In patients who did not suffer
from VAP, no difference was found regarding mean ± SD
length of hospital stay between periods 1 and 2 in the
intervention group (9.3 ± 11.9 days vs. 9.9 ± 14.8 days,
respectively, P = 0.5), whereas it decreased in the control
group (11.3 ± 13.0 days vs. 9.1 ± 9.9 days respectively,
P <0.001).
Outcome
In the intervention group with surveillance interrupted
in 2007, all-cause in-hospital mortality increased from
13.5% (n = 60) to 18.8% (n = 91) between periods 1 and
2 (P = 0.028). In the control group, all-cause in-hospital
mortality was stable between the periods (P = 0.22).
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Effect of surveillance disruption on VAP incidence
The VAP attack rate rose in the intervention group
from 7.8% (n = 35) during period 1 to 17.1% (n = 84)
during period 2 (P <0.001) (Figure 1). The VAP attack
rate in the control group without surveillance disruption
did not change between periods 1 and 2 (P = 0.17).
VAP incidence increased after surveillance disruption
in the intervention group (incidence rate ratio (IRR) =
2.17, 95% CI 1.05 to 4.47, P = 0.036) independently of
VAP trend (Table 2), but remained unchanged in the
control group (IRR = 1.37, 95% CI 0.74 to 2.55, P =
0.31). Additional file 1 reports the covariables associated
with VAP occurrence after univariate analysis. After
adjusting for trends, gender, age, patient origin, immu-
nosuppression, diagnosis category, antibiotics and SAP-
SII at admission, the adjusted incidence of VAP rose
after surveillance disruption (IRR = 2.31, 95% CI 1.03 to
5.17, P = 0.042), but did not change in the control
group (IRR = 1.36, 95% CI 0.72 to 2.56, P = 0.35).
Discussion
The study objective was to assess the effect of HAI sur-
veillance disruption on VAP incidence in ICUs. We
observed increased VAP incidence in the unit with sur-
veillance disruption, independently of time-trends (IRR =
2.17, 95% CI 1.05 to 4.47, P = 0.036), and no change in
the group without surveillance disruption. The effect we
saw could be mainly explained by the lack of data feed-
back and counselling in unit A during 2007. Indeed, no
such outcome was seen in the control group. The effect
was robust because the same observation was made after
adjusting for gender, age, patient origin, immunosuppres-
sion, diagnosis category, antibiotics and SAPSII at
admission.
The infection control team would have been less present
without surveillance in ICUs, because surveillance needs
regular data collection completed by counselling for best
practices. In unit A, surveillance was interrupted because
of infection control team re-organisation in 2007 and was
continuous in 2004 to 2006 and 2008 to 2010. No change
in senior physicians occurred in 2007 in unit A. The infec-
tion control nurse responsible for HAI surveillance in
2004 to 2006 stopped doing so in 2007 because of over-
work, and other infection control practitioners were
assumed surveillance in 2008 to 2010. However, VAP defi-
nition conformed to a standardised protocol [15,21,22],
Table 1 Description of the study population by period and ICU, Edouard Herriot Hospital, Lyon (France), 2004-2010.
Characteristics Intervention group:
Interrupted surveillance, unit A
Control group:
Continuous surveillance, unit B
Period 1 2004 to
2006 (n = 448)
Period 2 2007 to
2010 (n = 492)
P Period 1 2004 to
2006 (n = 743)
Period 2 2007 to




Gender, male 308 (68.8) 320 (65.0) 0.23 439 (59.1) 531 (60.3) 0.63
Patient origin 0.004 <0.001
Home 70 (15.6) 114 (23.2) 421 (56.7) 421 (47.8)
Other unit/hospital 378 (84.4) 378 (76.8) 322 (43.3) 460 (52.2)
Immunosuppresseda 153 (34) 263 (53) <0.001 98 (13.2) 175 (19.9) <0.001
Diagnosis categorya <0.001 0.060
Medical 265 (59.2) 161 (32.7) 660 (88.8) 807 (91.6)
Surgery 183 (40.9) 331 (67.3) 83 (11.2) 74 (8.4)
Antibioticsa 284 (63.4) 230 (46.8) <0.001 397 (53.4) 629 (71.4) <0.001
Deceased in-hospital 60 (13.5) 91 (18.8) 0.028 236 (31.9) 256 (29.1) 0.22
Continuous variable,
mean (SD)
Age, yearsa 56.3 (14.9) 58.5 (15.5) 0.022 61.1 (16.4) 60.7 (59.6) 0.61
SAPSIIa 51.7 (17.9) 45.4 (21.0) <0.001 55.6 (19.8) 55.5 (18.8) 0.95
Length of hospital stay, days 12.2 (18.6) 15.3 (25.7) 0.038 14.8 (20.3) 12.0 (17.0) 0.0023
Length of invasive mechanical
ventilation, days
7.7 (14.5) 11.3 (24.7) 0.007 11.1 (19.0) 8.5 (14.5) 0.0015
Incidence of VAP
Number of VAP 35 84 68 99
Attack rateb 7.8 17.1 <0.001 9.2 11.2 0.17








NOTE: CI, confidence interval; SD, standard deviation; SAPSII, simplified acute physiological score II; VAP, ventilator-associated pneumonia. a At ICU admission. b
Number of VAP per 100 intubated patients. c Number of VAP per 1,000 intubation-days.
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and no change in the surveillance protocol occurred dur-
ing the study period. Also, we can be confident that VAP
incidence truly increased in unit A after surveillance
disruption.
Moreover, during surveillance disruption, the infection
control team provided no feedback of HAI surveillance
results to the ICU staff. Kasatpibal et al. [27] observed no
effect of surveillance programme implementation on the
incidence of surgical site infection; explanative factors
were poor support from hospitals, insufficient enforce-
ment by infection control teams and lack of cooperation
with surgeons. On the other hand, a good relationship
existed between ICUs and the infection control teams in
our hospital, and a previous study reported the impact of
standardised preventive measures in all units at risk of
HAI (ICUs, haematology units) [28]. The two ICUs inves-
tigated were also targeted by these control measures at the
same level. Usually, feedback meetings offer good opportu-
nities to discuss prevention practices, such as device utili-
sation and healthcare organisation. In addition, there are
multiple interactions between the infection control depart-
ment and frontline clinicians other than data feedback.
Some of them are: counselling for standard or isolation
precautions, investigation of HAI clusters or of HAI
caused by multidrug-resistant microorganisms, discussion
of specific VAP precautions. These interactions are not
Figure 1 Trend of ventilator-associated pneumonia incidence in ICU, Edouard Herriot Hospital, Lyon (France), 2004-2010. NOTE: The
intervention group was unit A with surveillance disruption in 2007, the control group was unit B with continuous surveillance. Period 1 (pre-test
period) comprised patients hospitalized during 2004 to 2006, period 2 (post-test period) involved patients hospitalized during 2008 to 2010.
During period 1, no difference in the VAP attack rate (number of VAPs per 100 intubated patients) was observed between units A and B (P =
0.43). During period 2, the VAP attack rate was higher in unit A compared to unit B (P = 0.002). In unit A, the VAP attack rate increased between
periods 1 and 2 (P <0.001). In unit B, the VAP attack rate did not change between periods 1 and 2 (P = 0.17).
Table 2 Incidence rate ratio of ventilator-associated pneumonia for trends and disruption in 2007 in ICU
Characteristics Intervention group:
Interrupted surveillance, unit A
Control group:
Continuous surveillance, unit B
Adjusted IRR of VAP (95% CI)a P Adjusted IRR of VAP (95% CI)a P
Bivariate model
Trend, per quarter 0.98 (0.93 to 1.03) 0.45 1.01 (0.97 to 1.05) 0.69
Period
Before surveillance disruptionb 1.00 (Ref.) 1.00 (Ref.)
After surveillance disruptionc 2.17 (1.05 to 4.47) 0.036 1.37 (0.74 to 2.55) 0.31
Full modeld
Trend, per quarter 0.98 (0.92 to 1.04) 0.43 1.02 (0.97 to 1.06) 0.50
Period
Before surveillance disruptionb 1.00 (Ref.) 1.00 (Ref.)
After surveillance disruptionc 2.31 (1.03 to 5.17) 0.042 1.36 (0.72 to 2.56) 0.35
NOTE: CI, confidence interval; IRR, incidence rate ratio; VAP, ventilator-associated pneumonia. aAfter multivariate Poisson regression. b Period 1 (2004 to 2006). c
Period 2 (2007 to 2010). d Adjusted for gender, age, patient origin, immunosuppression, diagnosis category, antibiotics and SAPSII at admission in the unit. The
two other variables, trend (per quarter) and period (period 1 vs. period 2), were forced in the model.
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formalised but are the cornerstone of a safety culture [29].
They may account for the impact of surveillance upon
rates.
Overall mortality, length of stay and length of invasive
mechanical ventilation increased after surveillance dis-
ruption in unit A. We did not record the causes of death.
Also, we could not attribute the excess mortality to
increased VAP occurrence. Changes in patient severity or
modification of care practices and therapeutics along
time could be other explanative factors. However, we did
not observe increased mortality or average length of stay
in the control unit. It has been suggested that studies on
VAP prevention could demonstrate benefits in patient
outcome (mortality and duration of stay) [18]. Here, we
discerned changes in VAP incidence, mortality and dura-
tion of stay in the group with surveillance disruption but
not in the control group. Moreover, mean duration of
hospital stay in patients who did not suffer from VAP did
not change between periods in the group with surveil-
lance disruption; also, the increased incidence of VAP in
this unit might have directly impacted global length of
stay. In addition, the analysis was adjusted for gender,
age, patient origin, immunosuppression, diagnosis cate-
gory, antibiotics and SAPSII at admission, but residual
confounding by severity of illness factors might exist.
Moreover, to the best of our knowledge, no significant
factors besides the break in surveillance occurred around
2007 or thereafter. There was no new major or expanded
surgical or medical programme. VAP prevention recom-
mendations did not change in 2007. The main factors
that could explain the increase in VAP rates after disrup-
tion of surveillance are lower data feedback and counsel-
ling in ICUs. No other intervention occurred in the unit
with surveillance disruption as well as in the control unit.
VAP incidence was stable in the ICU with continuous
surveillance. In contrast, an inverse relationship was
noted in the other ICU: the absence of surveillance cor-
related with an increased HAI rate. Disruption of active
surveillance could be viewed as a lack of “pressure” to
control HAI risk in ICUs. During period 2, in response
to learning of high VAP rates after surveillance disrup-
tion, infection control nurses and practitioners under-
took active counselling. Despite this active participation
of infection control staff, a residual effect of surveillance
disruption was seen as VAP incidence remained higher
in the unit for three years thereafter, while global HAI
trends were similar in the two units during period 2
(Figure 1).
Reversibility of the surveillance effect reinforces the cau-
sal link between HAI surveillance and prevention [30].
Temporality is clearly witnessed here because surveillance
disruption precedes the increase in VAP incidence. Other
reasons for the causal relationship between surveillance
and VAP prevention are the strength of the surveillance
disruption effect and plausibility of the preventive out-
come of surveillance with feedback to healthcare workers.
One could argue that the relationship between surveillance
and VAP prevention could be due to an intermediate
effect. However, we were unable to detail this intermediate
effect more precisely, if it existed.
Our study has some strengths. First, the data were col-
lected prospectively, based on a standardised protocol
and VAP definition [15,21,22]. Second, regression analy-
sis permitted us to estimate the effect of surveillance dis-
ruption while controlling for time-trends with potential
cofounders [26]. Third, the control group allowed us to
control the effects of history (events occurring between
periods 1 and 2 in addition to the intervention), instru-
mentation and regression to the mean as well as interac-
tion between these effects [17,19]. Thus, as advanced by
Harris et al. [19], the presence of a control group rein-
forced internal validity.
The major limitation of our study is the lack of rando-
misation of the intervention, which implies that the inter-
vention and control groups are not equivalent [19].
However, HAI surveillance is unit-based, and no indivi-
dual randomisation is possible. A multicenter study
would allow randomisation in clusters, but organisational
difficulties limited this perspective. Here, multivariate
analysis permitted us to take potential confounding fac-
tors into account. However, additional confounding fac-
tors, such as chronic co-morbidities (that is, diabetes,
renal failure, liver disease, heart disease) or source of
immunosuppression (that is, chemotherapy, tumour
necrosis factor blockers, steroids), would have been use-
ful but were not collected prospectively. Moreover, accu-
rate VAP diagnosis is difficult, and classification bias of
the disease cannot be excluded. However, as no alterna-
tive measure of infectious pulmonary complications
among ventilated ICU patients currently exists [31], we
applied standardised definitions. Moreover, this classifi-
cation bias might not be related to time. Another point is
the monocentric nature of the study that might limit gen-
eralisability of the findings. However, this design might
reinforce internal validity. Finally, no data on compliance
measures associated with VAP prevention (that is, head
of bed elevation, sedation vacation) were collected pro-
spectively. However, the protocols related to VAP pre-
vention were similar between the two units. Indeed,
infection control protocols were the same in both units
because they are standardised in University of Lyon
hospitals.
Conclusions
In summary, we observed an increase in VAP incidence,
length of stay and in-hospital mortality after HAI sur-
veillance disruption in ICU. Disruption of surveillance
induced lower data feedback and counselling in ICU.
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This finding suggests a specific effect of HAI surveil-
lance on VAP prevention and reinforces the utility of
surveillance systems. HAI surveillance should be consid-
ered as a mechanism to facilitate performance improve-
ment and infection control.
Continuous surveillance of HAI incidence in ICUs
requires major resources from both infection control
units and ICUs. However, it is important to continue to
improve this system for very probable direct benefits to
patients. Additional data are needed regarding the rea-
sons of stopping of surveillance as potential other pre-
ventive measures not done during this period.
Cost-effectiveness analysis is warranted for long-term
implementation of HAI surveillance in ICUs.
Key messages
- The preventive impact of HAI surveillance is not well
known.
- It is difficult to perform controlled randomised trials
to confirm or refute this premise, and a quasi-experi-
mental design with a control group could be an alterna-
tive approach to the question.
- The objective was to investigate the effect of HAI
surveillance disruption on VAP incidence.
- VAP incidence, all-cause mortality and length of stay
increased in one ICU after surveillance disruption, and
no change was observed in the control unit with contin-
uous surveillance.
- HAI surveillance with data feedback and counselling
should be considered as a mechanism to facilitate per-
formance improvement and infection control in ICUs.
Additional material
Additional file 1: Additional Table 1. Covariables associated with
ventilator associated pneumonia incidence in unit A (interrupted VAP
surveillance) vs. unit B (continuous VAP surveillance), Edouard Herriot
Hospital, 2004 to 2010 - univariate Poisson regression. CI, confidence
interval; IRR, incidence rate ratio; SAPSII, simplified acute physiological
score II; VAP, ventilator-associated pneumonia.
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